Obstructive Sleep Apnea-Hypopnea Syndrome
Conditions
Interventions
Experimental group:Intravenous Ciprofol (0.375 mg/kg) before examination
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Preoperatively diagnosed with OSAHS and scheduled for DISE. 2. Aged 18–60 years. 3. ASA physical status classification I–III.
Exclusion criteria
Exclusion criteria: 1. Use of sedatives or analgesics within the past 3 months, or allergy/contraindication to opioids, propofol, ciprofol, or any of their components. 2. Acute heart failure, unstable angina, myocardial infarction within 6 months prior to screening, resting heart rate <50 beats per minute on ECG, third-degree atrioventricular block, severe arrhythmia, moderate to severe valvular heart disease. 3. Other severe respiratory diseases, such as acute respiratory infection, acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, etc. 4. Psychiatric disorders (e.g., schizophrenia, mania, bipolar disorder, psychosis), long-term use of psychotropic medications, or cognitive dysfunction. 5. Severe hepatic or renal insufficiency. 6. Pregnancy or lactation. 7. Participation in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time-weighted average of hypoxemia;Sedation success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulse oxygen saturation;non-invasive blood pressure;Heart rate;BIS Index;Incidence rate of adverse events; | — |
Countries
China
Contacts
Public ContactHe Xin
Xiangya Hospital, Central South University
Outcome results
None listed